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SET domain-containing 2 (SETD2) is responsible for the trimethylation of histoneH3 lysine36 (H3K36me3) and is one of
the genesmost frequentlymutated in clear cell renal cell carcinoma (ccRCC). It is located at 3p21, one copy ofwhich is
lost in themajority of ccRCC tumors, suggesting that SETD2might function as a tumor suppressor gene. However, the
manner in which loss of SETD2 contributes to ccRCC development has not been studied in renal primary tubular
epithelial cells (PTECs). Therefore, we studied the consequences of SETD2 knockdown through lentiviral shRNA in
human PTECs. Consistent with its known function, SETD2 knockdown (SETD-KD) led to loss of H3K36me3 in PTECs.
In contrast to SETD2 wild-type PTECs, which have a limited proliferation capacity; the SETD2-KD PTECs continued to
proliferate. The expression profiles of SETD2-KD PTECs showed a large overlap with the expression profile of early-
passage, proliferating PTECs, whereas nonproliferating PTECs showed a significantly different expression profile.
Gene set enrichment analysis revealed a significant enrichment of E2F targets in SETD2-KD and proliferating PTECs as
compared with nonproliferating PTECs and in proliferating PTEC compared with SETD2-KD. The SETD2-KD PTECs
maintained low expression of CDKN2A and high expression of E2F1, whereas their levels changed with continuing
passages in untreated PTECs. In contrast to the nonproliferating PTECs, SETD2-KD PTECs showed no β-galactosidase
staining, confirming the protection against senescence. Our results indicate that SETD2 inactivation enables PTECs to
bypass the senescence barrier, facilitating a malignant transformation toward ccRCC.
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Clear cell renal cell carcinoma (ccRCC) represents the most common
and lethal subtype of kidney cancer, accounting for 80% to 90% of
renal cell carcinomas and 3% of all cancers [1]. A better
understanding of the processes that underlie ccRCC development
might help in designing more successful ways to treat these tumors
[2]. ccRCC arises from the primary tubular epithelial cells (PTECs) of
the kidney [3], but the malignant transformation process is poorly
understood. The most common genomic aberration in ccRCC is 3p
loss [4], indicating the presence of ccRCC-associated tumor
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Hippel–Lindau (VHL) [5], which maps to 3p25 and is mutated in
approximately 55% of tumors [6]. In recent years, three additional 3p
genes (PBRM1, BAP1, and SETD2) have been identified as being
frequently mutated in ccRCC. Mutations in SETD2 were first
reported in two independent studies. Dalgliesh et al. identified
SETD2-inactivating mutations in 15/342 ccRCC cases [6], and we
identified SETD2-inactivating mutations in 5/10 ccRCC-derived cell
lines [7]. SETD2-inactivating mutations occur at a frequency of 11%
in ccRCC [8,9]. According to the Catalogue of Somatic Mutations in
Cancer database (http://cancer.sanger.ac.uk/cosmic, accessed in
October 2015), ccRCC is the only tumor type that SETD2 ranks
into the top five mutated genes. Together, these studies support the
relevance of SETD2 inactivation in the development of ccRCC. Loss
of one allele of SETD2 and functional inactivation of the second allele
by a point mutation are consistent with Knudson’s classic two-hit
model to inactivate TSGs.
SETD2 is a histone methyltransferase responsible for the histone
H3 lysine 36 trimethylation (H3K36me3), a histone mark enriched
at the gene body of actively transcribed genes [10]. The SRI domain
of SETD2 interacts with RNA-polymerase II, causing SETD2 to be
present during transcription. Many of the biological processes in
which SETD2 has been suggested to participate revert to its presence
during the transcriptional process. In ccRCC-derived cell lines, loss of
3p and mutation of the remaining SETD2 allele result in a complete
loss of H3K36me3, whereas cell lines with one functional SETD2
allele show at most slightly reduced or even normal H3K36me3 levels
[7]. It is still unclear how SETD2 inactivation might contribute to the
pathogenesis of ccRCC. We aimed to determine if SETD2 acts as a
TSG in ccRCC and how SETD2 inactivation contributes to the
malignant transformation.
Material and Methods
A schematic representation of the workflow and detailed experimental
procedures are presented in the Supplementary material and methods.
Isolation of PTECs and Cell Cultures
PTECs were isolated from the healthy human kidney cortex segment.
The isolation procedures and phenotype identification were performed as
previously described [11]. Both PTECs and HKC8 were maintained in
Dulbecco’s modified Eagle’s medium/F-12 GLUTMAX-1 containing
10% fetal bovine serum (FBS), 100 U/ml of penicillin, 100 μg/ml of
streptomycin, 1% Insulin-Transferrin-Selenium, and 5 ng/ml of
epidermal growth factor (EGF). Human embryonic kidney 293T
(HEK293T) cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum (FBS), 100 U/ml of
penicillin, and 100 μg/ml of streptomycin (all used for cell culturing are
from Sigma-Aldrich, St. Louis, MO). All the cells were maintained at
37°C under humidified air containing 5% CO2. Mycoplasma, bacteria,
and fungi were tested as negative in these cultures.
ShRNA Constructs, Lentiviral Transductions, and Growth
Competition Assay
Oligos (Eurogentec, Seraing, Belgium) to generate shRNA constructs
were cloned into the pGreenpuro lentivector (Systems Biosciences,
Mountain View, CA) using standard procedures (see shRNA construct
sequences in Supplementary Table 1). Lentiviral particles were produced
by calcium phosphate–mediated transfection of HEK293T cells.
Transduction of target cells was performed with multiple dilutions of
concentrated virus stock in the presence of 4 μg/ml of polybrene(Sigma-Aldrich). Green fluorescent protein (GFP) was measured on the
FACS Calibur flow cytometer (BD Biosciences, San Jose, CA), and data
were analyzed with Kaluza Flow Analysis Software v 1.3 (Beckman
Coulter, Brea, CA). Cultures with a high percentage of transduced cells
were used to confirm knockdown of SETD2.Cell cultures with amix of
GFP+ and GFP− cells were used in the GFP-competition assay.
Percentages of GFP+ cells were normalized to the percentage of GFP+
cells at the first measurement. GFP was measured at indicated time
points.
RNA Isolation and Reverse-Transcription Quantitative
Polymerase Chain Reaction (RT-qPCR)
Total RNA was isolated by Gene JET RNA purification kit
(Fermentas, St. Leon-Rot, Germany). RNA quality was evaluated on
an HT RNA LabChip GX/GXII kit (Caliper GX; Life Sciences,
Hopkinton, MA). To quantify the expression levels of target genes,
equal amount of RNA was synthesized to first-strand cDNA using the
RevertAid H Minus First Strand cDNA synthesis kit (Thermo Fisher
Scientific, Rockford, IL). Quantitative PCR was performed on the
ABI 7900HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA) with iTaq Universal SYBR Green Supermix
(Bio-Rad, Hercules, CA), and the results were analyzed by SDS 1.3.0
software (Life Technologies, Foster City, CA). Unpaired one-tailed t tests
were used to determine whether significant changes in SETD2 levels were
obtained upon shRNA-mediated knockdown (see RT-qPCR primers in
Supplementary Table 1).
Histone Isolation and Western Blot Analysis
Cells were lysed in TEB buffer (PBS containing 0.5% Triton X 100
[v/v], 2 mM phenylmethylsulfonyl fluoride, and 0.02% [w/v] NaN3),
and histones were isolated by acid extraction. Histones extracts were
separated with 15% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred to a PVDF membrane (Roche,
Mannhein, Germany) for blotting. The proteins of interest were probed
with antibodies against tri-methyl-histone H3 (Lys36) (1:1000; Cell
Signaling, Danvers, MA) or histone H3 (1:1000; Cell Signaling). Target
proteins were detected with HRP-conjugated Alexa Fluor 488 Donkey
Anti-Rabbit IgG antibody (H + L) (1:10,000; Life Technologies, NY).
Positive staining was visualized by incubation with Lumi-light Western
Blotting substrate (Roche). Images were captured by the ChemiDOC
MP imaging system with Image lab v4.1 software (Bio-Rad).
Microarray and Expression Analysis
A custom-designed microarray was used for expression profiling
(Agilent ID 050524), and the procedure was performed according to
the manufacturer’s instructions (Agilent Technologies, Santa Clara,
CA). Total RNAwas labeled using the Low Input Quick Amp Labeling
Kit and the Cyanine5 CTP Dye Pack (Agilent Technologies). cRNA
was purified using the RNeasy Mini Kit (Qiagen, Valencia, CA),
quantified on a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific), and hybridized on the custom array using the Gene
Expression Hybridization Kit (Agilent Technologies). Arrays were
scanned with the Agilent DNA Microarray Scanner and analyzed with
Agilent Feature Extraction software v 10.7.3.1. The resulting raw data
were analyzed with GeneSpring GX 13.1.1 software (Agilent
Technologies). To exclude a possible bias caused by the multiplicity
of infection (MOI), we performed principle component analysis and
compared wild-type (WT) to nontargeting (NT) PTECs at both day 6
and day 16. In addition, we performed a moderated t test with
Bonferroni family-wise error rate (FWER) multiple testing correction.
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significant difference post hoc test was used to identify differentially
expressed genes between the three experimental groups, and Bonferroni
FWER adjusted P values b .05 were considered statistically significant.
The experimental groups were 1) proliferating PTECs at day 6
including both WT and NT PTECs, 2) nonproliferating WT and NT
PTECs at day 16, and 3) SETD2-KD PTECs at day 25. Microarray
data are available through the GEO database (GSE72792).
Senescence β-Galactosidase (β-gal) and Immunohistochemistry
(IHC) Staining
The senescence β-gal Staining Kit (Cell Signaling) was used according
to the manufacturer's instructions. Images were captured by TissueFax
(TissueGnostics, Vienna, Austria) equipped with Zeiss objective LD
"Plan-Neofluar" 20×/0.4 Corr Dry, Ph2 objectives. Formaldehyde- or
acetone-fixed cells were processed for IHC staining by standard
procedures. Representative images were captured by an Olympus
BX41 microscope (Olympus, Hamburg, Germany). Antibodies used in
the staining are listed in the Supplementary material and methods.
Results and Discussion
SETD2 Depletion in Immortalized Kidney Epithelial Cell Lines
To study the role of SETD2 in epithelial cells, we transduced
HEK293T and HKC8 cells with lentiviruses containing SETD2-
targeting or NT shRNAs coexpressed with GFP. Both SETD2 shRNA
constructs induced a 60% to 70% decrease in SETD2mRNA levels. A
virtual absence of H3K36me3, commonly used as a measure of SETD2
loss [10], in SETD2 shRNA-treated HEK293 cells confirmed efficient
downregulation of SETD2 at the protein level (Figure 1A). To study the
effect of SETD2 knockdown on cell growth, we performed a GFP
competition assay in both cell lines. In HEK293T cells, a significant
reduction of GFP+ SETD2-KD cells (60%-80%) was observed at day
20 for both shRNA constructs relative to the GFP+ percentage at day 3.
In HKC8 cells, the reduction was also significant, although less
pronounced, with a drop of 40% to 60%. No significant differences
were observed in the growth competition assays for the NT-shRNA
construct transduced cell lines (Figure 1B). Thus, SETD2 depletionFigure 1. SETD2 knockdown in immortalized kidney epithelial cell line
directed against SETD2 results in a decreased level of SETD2mRNAdet
for normalization. Ctrl, wild-type HEK293T cells; NT, nontargeting shRN
of the global level of H3K36me3 in SETD2 knockdown cells as compare
level of histone H3 was used as a loading control. (B) Growth competiti
transduced with a nontargeting sequence (NT) or with constructs targe
was measured at the indicated time points (X-axis). The relative cha
GFP-positive cells onday 3 (Y-axis). The data are presented asmean±SD
testing correction showed a significant difference of SETD2-sh1 and -scaused a marked decrease in cell growth in immortalized human
embryonic kidney (HEK293T) cells and kidney epithelial (HKC8)
cells. The decrease in GFP+ cells might be related to a reduced
transcription elongation rate of multiexon protein coding genes as a
consequence of loss of H3K36me3 [12]. These findings are not
consistent with a tumor suppressor function of SETD2 in ccRCC.
However, the impact of SETD2 knockdown in these immortalized and
highly proliferating kidney cell lines might not represent an optimal
model to study the tumor-suppressing function of SETD2 in ccRCC.
SETD2-KD in PTECs
To further study the possible tumor suppressor function of SETD2
in ccRCC oncogenesis, we switched to renal primary tubular epithelial
cells (PTECs), which are generally regarded as the normal counterparts
of ccRCC [3]. These PTECs can be isolated from the kidney cortex
segment and cultured in vitro for a limited number of population
doublings [13]. We isolated PTECs and authenticated their phenotype
as described previously [11].
Early-passage PTECs derived from three different individuals were
transduced with viral particles containing SETD2-shRNA constructs.
Again, both constructs induced a significant decrease in SETD2
mRNA levels (40%-60%) and an almost complete loss of
H3K36me3 (Figure 2A). This loss of H3K36me3 is consistent
with a complete functional loss of SETD2 as observed in ccRCC cell
lines caused by loss of one allele and an inactivating mutation in the
remaining SETD2 allele [7]. We next assessed the effect of SETD2
knockdown in a GFP-competition assay. At day 22 of the growth
competition assay, the proportion of GFP+ cells showed a significant
increase of 140% and 70% in SETD2-sh1 and SETD2-sh2
transduced PTECs, respectively, over the GFP− cells compared
with day 2. The percentage of GFP+ cells in the NT-shRNA
transduced PTECs (NT-PTECs) did not show a significant change
over time (Figure 2B). These experiments revealed an apparent
growth advantage of SETD2-KD PTECs relative to SETD2-WT
PTECs consistent with a possible tumor suppressor function of
SETD2. The proliferative capacity of untreated and NT-shRNA–
treated PTECs gradually decreased, and cells stopped proliferating ats. (A) Transduction at high MOI of HEK293T cells with sh1 and sh2
ermined by RT-qPCR. Results are presented as 2− Ct;HPRTwas used
A transduced HEK293T cells. Western blot shows a strong decrease
d with control HEK293T cells and the NT-treated HEK293T cells. The
on assay in HEK293T and HKC8 cells. HEK293T and HKC8 cells were
ting SETD2 (sh1 and sh2) at lowMOI. The percentage of GFP+ cells
nges in GFP-positive cells were normalized to the percentage of
from triplicate experiments.One-wayANOVAwithDunnettmultiple
h2 compared with NT, **P b .01, ***P b .001.
Figure 2. Knockdown of SETD2 in kidney PTECs. (A) SETD2 knockdown in PTECs. PTECs were transduced with shRNA constructs as
described in Figure 1A. The relative abundance of SETD2 mRNA was normalized to RNA polymerase II (RP II). Y-axis shows the 2− Ct from
three independent experiments (mean ± SD, one-way ANOVA with Dunnett multiple testing correction, *P b .05, **P b .01). The level of
H3K36me3 in SETD2 wild-type PTECs and shRNA transduced PTECs was shown by Western blotting; Histone H3 was used as a loading
control. (B) Growth competition assay in PTECs. PTECs were transduced with shRNA virus particles as described in Figure 1B; GFP-positive
cells were measured at the indicated time points (X-axis). The fold change relative to the percentage at day 2 (Y-axis) is shown. The data are
presented asmean± SD of three independent experiments. One-way ANOVAwith Dunnett multiple testing correction showed a significant
difference of SETD2-sh1 and -sh2 comparedwith NT, *P b .05, **P b .01, ***P b .001. (C) Immunohistochemical staining of SETD2-KD PTECs
at day 40 with four epithelial markers (CK8/18, EMA, CA AE1/3, and C5α receptor), one fibroblast marker (α-SMA), and one proximal tubular
marker (L-FABP). The stainingwas done in three independent PTEC cultures, and the images shown represent one of these cultures (400×).
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proliferative capacity of PTECs [13]. We therefore stopped the
GFP-competition assay at day 22.
SETD2-KD PTECs continued to proliferate until we stopped these
cultures at day 40. Staining of the SETD2-KD PTECs at day 40
revealed an immunophenotype consistent with the wild-type PTECs at
passage 3 (Supplementary Figure 1), i.e., positive for epithelial markers
cytokeratin 8/18 (CK 8/18), epithelial membrane antigen (EMA),
cytokeratin clone AE1/3 (CK AE1/3), and C5α receptor (c5α R) and
negative for fibroblast marker α smooth muscle actin (α-SMA).
SETD2-KD PTECs were also positive for liver-type fatty acid–binding
protein 1 (L-FABP) (Figure 2C), a marker of human kidney proximal
tubular cells [14].
Thus, we showed that SETD2 knockdown in PTECs abolished
H3K36me3 and rendered a relative proliferative advantage while
preserving the expected immune phenotype of PTECs.
Expression Signature of SETD2-KD PTECs
To elucidate the mechanism underlying the enhanced proliferative
capacity of SETD2-KD PTECs, we generated gene expression
signatures of proliferating SETD2-WT PTECs at day 6 (WT-day 6),
nonproliferating SETD2-WT PTECs at day 16 (WT-day 16), and
SETD2-KD PTECs at day 25 (KD-day 25) that had overcome the
restricted proliferating capacity. PTECs transduced with NT shRNA
constructs (days 6 and 16) were used as controls. To obtain sufficient
cells for the analysis, we infected theNT cells at a highMOI.To exclude
a potential bias caused by comparing untreated PTECs to PTECS
infected with a high MOI (NT) or a lowMOI (SETD2-KD shRNAs),
we carried out a principle component analysis (Supplementary
Figure 2). Component 1 discriminated between nonproliferating
WT- and NT-day 16 cells and the proliferating WT/NT-day 6 and
KD-day 25 cells. Component 2 discriminated between WT/NT-day 6
and the KD-day 25 samples. NT cells clustered together with the WT
cells at both day 6 and day 16, indicating that MOI did not affect the
expression profile.Moreover, no significant differences in the expressionprofiles between the WT and NT cells were detected. These analyses
clearly indicate that the high MOI used for the NT short hairpin
transduction did not affect the expression signature of PTECs.
One-way ANOVA with Bonferroni FWER multiple testing
correction revealed 227 differentially expressed genes between the
three experimental groups, i.e., proliferating untreated/NT PTECs at
day 6 (WT/NT-day 6), nonproliferating WT/NT-day 16 PTECS, and
proliferating SETD2-KD day 25 PTECs. Two hundred seven genes
were differentially expressed between WT/NT-day 6 and WT/NT-day
16PTECs, 207 genes between SETD2KD-day 25 andWT/NT-day 16
PTECs, and 148 genes betweenWT/NT-day 6 and SETD2KD-day 25
PTECs (Supplementary Table 2). Unsupervised hierarchical clustering
revealed one cluster with all proliferating WT/NT-day 6 and SETD2
KD-day 25 PTECs and a second cluster with the nonproliferating
WT/NT-day 16 PTECs (Figure 3A). The samples in the first cluster
showed a further grouping, with one tree containing theWT/NT-day 6
PTECs and one tree containing the SETD2 KD-day 25 PTECS.
To characterize the expression differences between these three
experimental groups, a gene set enrichment analysis (GSEA) for biological
function was performed (Table 1). In comparison to WT/NT-day 6
PTECs, SETD2KD-day 25 PTECs showed a significant enrichment of
nine gene sets (false discovery rate [FDR] b 0.01). Activation of the
TNFαvia–NF-κB signaling cascade promotes cell proliferation in
ccRCC cell lines [15]. Epithelial-Mesenchymal-Transition (EMT) has
been shown as an important expression signature of ccRCC [16]. We
previously identified differential expression of a set of EMT-related
microRNAs between PTEC cells and ccRCC-derived cell lines [17].
Moreover, activation of a membrane-bound interleukin-15 isoformwas
also shown to stimulate EMT [18]. These studies indicate an oncogenic
potential of the SETD2-KD PTECs. Seven gene sets, including
E2F_TARGETS and G2M_CHECKPOINT, were enriched in WT/
NT-day 6 PTECs in comparison to KD-day 25 cells.
Compared with WT/NT-day 16 PTECs, two gene sets were
specifically enriched in SETD2 KD-day 25 PTECs and two in WT/
NT-day 6 PTECs. Four gene sets were significantly enriched in
Figure 3. SETD2-KD PTECs at day 25 shows an expression signature comparable to proliferating PTECs at day 6. (A) Heat map of the 238
probes (representing 227 genes) differentially expressed between the three predefined groups: SETD2-WT (CON and NT) PTECs at day 6
(WT-day 6), SETD2-WT (CON and NT) PTECs at day 16 (WT-day 16), and SETD2-KD (sh1 and sh2) PTECs at day 25 (KD-day 25). The heat
map was generated with unsupervised clustering using Euclidian distance calculated as distance metric. CON and NT samples clustered
closely together in each of the three PTECs, despite the difference in being untransduced and transduced at a high MOI. (B) GSEA
comparisons of WT-day 6, KD-day 25, and WT-day 16 PTECs using the hallmark gene sets retrieved from MSigDB (n = 50, FDR b 0.01).
Enrichment plots of the E2F targets expression signature are presented. Normalized enrichment score (NES) and FDR q-value
are indicated.
Table 1. Enriched Gene Sets in WT-Day 6 and KD-Day 25 PTECs Compared with WT-Day 16 PTECs
Hallmark Gene Set NES/FDR q-Value NES/FDR q-Value NES/FDR q-Value
KD-Day 25 vs WT-Day 16 WT-Day 6 vs WT-Day 16 KD-Day 25 vs WT-Day 6
E2F_TARGETS 2.81/b0.001 – 2.95/b0.001 – – 2.43/b0.001
G2M_CHECKPOINT 2.66/b0.001 – 2.82/b0.001 – – 2.19b0.001
UV_RESPONSE_DN 1.98/b0.001 – – – 1.93/b0.001 –
MITOTIC_SPINDLE 1.98/b0.001 – 1.86/b0.005 – – –
MYC_TARGETS_V1 1.93/b0.001 – 2.34/b0.001 – – 2.12/b0.001
EPITHELIAL_MESENCHYMAL_TRANSITION 1.82/b0.005 – – – 2.05/b0.001 –
DNA_REPAIR – – 1.73/b0.01 – – –
MYC_TARGETS_V2 – – 2.06b0.001 – – 1.79/b0.005
TNFA_SIGNALING_VIA_NFKB – – – 2.34/b0.001 2.39/b0.001 –
INFLAMMATORY_RESPONSE – – – 1.97/b0.005 1.77/b0.005 –
IL6_JAK_STAT3_SIGNALING – – – 1.77/b0.01 – –
KRAS_SIGNALING_DN – – – 1.74/b0.01 – –
HYPOXIA – – – – 1.97/b0.001 –
APOPTOSIS – – – – 1.83/b0.005 –
INTERFERON_GAMMA_RESPONSE – – – – 1.81/b0.005 –
COMPLEMENT – – – – 1.75/b0.005 –
IL6_JAK_STAT3_SIGNALING – – – – 1.66/b0.01 –
OXIDATIVE PHOSPHORYLATION – – – – – 2.05/b0.001
BILE_ACID_METABOLISM – – – – – 1.91/b0.001
ESTROGEN_RESPONSE_LATE – – – – –– 1.74/b0.01
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accordance with their proliferation status, both WT/NT-day 6 and
SETD2 KD-day 25 PTECs showed significant enrichment of
E2F_TARGETS (Figure 3B), G2M_CHECKPOINT, MITOTIC_
SPINDLE, and MYC_TARGETS_V1 gene sets in comparison to the
nonproliferating WT/NT-day 16 PTECs. G2/M checkpoint genes
regulate the transition of G2 to M phase in cells and prevent division of
cells with DNA damage [19]. The E2F family of transcription factors
orchestrates the expression of hundreds of genes in multiple biological
processes, including senescence [20]. Collectively, these results
demonstrate that SETD2-KD PTECs remain in an active proliferationFigure 4. SETD2 inactivation prevents PTECs from senescence by ac
SETD2-day 20 and SETD2-day 40 PTEC cultures. Representative micr
cells was performed by using ImageJ software (National Institutes of
of three independent experiments (right panels). (B) ThemRNA expres
SETD2-WT PTECs at day 16 (WT-day 16), and SETD2-KD PTECs at da
of target genes was normalized to RP II. The results are presented a
One-way ANOVA with Dunnett multiple testing corrections showed
compared with nonproliferating WT-day 16 PTECs. *P b .05, **P b .0status well beyond a passage that would have caused senescence in the
WT-PTECs. Given the known association between E2F targets and
senescence, as well as the results of the growth competition assay, we
next studied the expression of known senescence markers.
Inhibition of CDKN2A-E2F signaling in SETD2-KD PTECs
Senescent cells are characterized by growth arrest, enlarged and flat
cellular morphology, and an expression profile characterized by
senescence-associated genes. The most commonly used marker to
identify senescent cells is β-gal activity [21]. As shown in Figure 4,
almost all NT-day 20 PTECs (both GFP+ and GFP−) stainedtive E2F signaling. (A) GFP and β-gal staining results of NT-day 20,
oscopic views are shown. Quantification of GFP- and β-gal–positive
Health, Bethesda, MD). The results are present as mean ± SD value
sion of CDKN2A and E2F1 in SETD2-WT PTECs at day 6 (WT-day 6),
y 25 (KD-day 25) was determined by RT-qPCR. The expression level
s 2− Ct values of three independent experiments with mean ± SD.
significant differences between WT-day 6 and KD-day 25 PTECs
1.
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SETD2-KD cultures at day 20, containing both transduced GFP+/
SETD2-KD PTECs and nontransduced GFP-/SETD2-WT PTECs,
only a subpopulation of the cells stained positive for β-gal. After 40
days, almost all SETD2 KD cells were negative for β-gal while being
positive for GFP. The decrease of β-gal–positive cells, in combination
with the increasing number of GFP+ cells in the SETD2-KD PTEC
culture, is consistent with a rescue of senescence of the SETD2-KD
cells. These results indicate that knockdown of SETD2 prevents the
transition of proliferating PTECs to nonproliferating, senescent
PTECs.
The two main pathways associated with regulation of senescence are
the tumor protein (TP)53-cyclin-dependent kinase inhibitor 1A
(CDKN1A) and the CDKN2A-E2F pathway [22]. Activation of
TP53 results in induction ofCDKN1A and senescence. The expression
levels ofTP53 did not change, whereas its downstream targetCDKN1A
was increased in both nonproliferating WT/NT-day 16 PTECs and
proliferating SETD2 KD-day 25 PTECs (Supplementary Figure 3).
Activation of CDKN2A induces senescence by inhibiting E2F family
members through binding to the retinoblastoma protein. As GSEA
showed enrichment of E2F targets in WT/NT-day 6 and SETD2
KD-day 25 PTECs comparedwithWT/NT-day 16 PTECs, we studied
the expression ofCDKN2A and E2F1 in these three cohorts. Compared
with WT/NT-day 6 PTECs, we observed a significant increase of
CDKN2A and a significant decrease of E2F1 inWT-day 16 PTECs. In
SETD2 KD-day 25 PTECs, the expression ofCDKN2A and E2F1was
maintained at levels comparable to WT/NT-day 6 PTECs (Figure 4B).
These findings are consistent with a previous report showing that the
expression of the E2F1 was decreased in senescent cells, whereas E2F1
overexpression enabled resistance to senescence in primary fibroblast
cells [23]. Thus, it appears that SETD2 knockdown prevents
senescence in PTECs by maintaining the CDKN2A-E2F pathway. In
the immortalized HEK293T cells, we observed decreased expression of
both CDKN2A and E2F1 as a result of SETD2-KD (Supplementary
Figure). Since the phosphorylation of RB is abolished as a result of the
immortalization, the decreased expression of CDKN2A cannot activate
E2Fs. The decreased expression level of E2F1 might be caused by the
genome-wide absence of H3K36me3 in gene bodies.
To examine if SETD2 inactivation could reverse the senescent
nature of PTECs at high passage number, β-gal staining was
performed on PTECs 6 days after transduction with lentiviral
SETD2-shRNA at passage 6 (day 20). Although the majority of the
cells were GFP+, they also stained positive for β-gal (Supplementary
Figure 5), indicating that the senescent state could not be reverted
upon SETD2 knockdown.
Our data show that SETD2 inactivation represents an escape of
senescence mechanism of PTECs, in line with its tumor suppressor
function in ccRCC. This is consistent with the proposed role of SETD2
inactivation in acute leukemia [24]. Senescence is a response that prevents
proliferation of cells with DNA damage, and it serves as a barrier for
malignant transformation [19]. We now show that SETD2 inactivation
in PTECs bypasses the senescence barrier bymaintainingCDKN2A-E2F
signaling. Collectively, these studies emphasize the importance of the
senescence-associated pathway in the development of ccRCC.
The major known consequence of SETD2 inactivation is loss of
H3K36me3 on actively transcribedmultiexon genes. This histonemark
is recognized by so-called readers, most often by virtue of their PWWP
domain [25]. These readers are important components of several
cellular pathways that are linked to cancer. SETD2 mutated ccRCCtumors and/or cell lines showed altered chromatin accessibility,
resulting in widespread transcript processing defects [26]. This is
consistent with the known regulatory role of H3K36me3 methylation
on transcription regulation [12]. Loss of H3K36me3 in ccRCC
prevented recruitment of the mutS homolog 6, which is essential for
DNA mismatch repair [27], and recruitment of Lens epithelium-
derived growth factor, which is required for homologous recombination
ofDNAdouble-strand breaks [28]. Loss ofH3K36me3 also hinders the
recruitment of RAD51 to DNA damage sites, resulting in failure of the
TP53-mediatedDNA damage response [29]. A disrupted interaction of
BRCA1 with RAD51 was shown to lead to microtubule organizing
center amplification, causing chromosomal instability [30]. Thus, it
might be speculated that loss of SETD2 leads to accumulation of DNA
damage. However, it remains unknown how SETD2 loss exactly
prevents senescence in PTECS; most likely, the effect is modulated by
CDKN2A, which is strongly induced upon senescence and prevents
induction of E2Fs and their targets. On the other hand, it cannot be
excluded that another, undiscovered mode of action of SETD2 is
responsible for the phenotype as observed upon SETD2-KD. Loss of a
direct interaction of SETD2 with TP53 could play a role in this process
[31]. The regulation of several TP53 downstream targets appeared to be
dependent on its interaction with SETD2. Loss of puma, one of these
targets, is suggested to prevent DNA-damage–induced apoptosis [32].
Conclusions
In summary, we demonstrate that functional loss of SETD2 enables
PTECs to bypass the senescence barrier bymaintaining CDKN2A-E2F
signaling. The prolonged proliferating potential might result in
accumulation of DNA damage and thereby result in the development
of ccRCC. Our results thus support a tumor suppressor role for SETD2
in ccRCC, consistent with Knudson’s two-hit model.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.04.005.
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